These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32972825)

  • 61. Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela.
    Convit J
    Clin Dermatol; 1996; 14(5):479-87. PubMed ID: 8889325
    [No Abstract]   [Full Text] [Related]  

  • 62. Transforming growth factor-beta in tegumentary leishmaniasis.
    Barral-Netto M; Barral A
    Braz J Med Biol Res; 1994 Jan; 27(1):1-9. PubMed ID: 8173524
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessment of intralesional cytokine profile of cutaneous leishmaniasis caused by Leishmania donovani in Sri Lanka.
    Galgamuwa LS; Sumanasena B; Iddawela D; Wickramasinghe S; Yatawara L
    BMC Microbiol; 2019 Jan; 19(1):14. PubMed ID: 30642262
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mammalian host defense peptides and their implication on combating Leishmania infection.
    Abdossamadi Z; Seyed N; Rafati S
    Cell Immunol; 2016 Nov; 309():23-31. PubMed ID: 27729107
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Imaging of the host/parasite interplay in cutaneous leishmaniasis.
    Millington OR; Myburgh E; Mottram JC; Alexander J
    Exp Parasitol; 2010 Nov; 126(3):310-7. PubMed ID: 20501336
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differential properties of CBA/J mononuclear phagocytes recovered from an inflammatory site and probed with two different species of Leishmania.
    Gomes IN; Calabrich AF; Tavares Rda S; Wietzerbin J; de Freitas LA; Veras PS
    Microbes Infect; 2003 Apr; 5(4):251-60. PubMed ID: 12706438
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation.
    Antonelli LR; Dutra WO; Almeida RP; Bacellar O; Gollob KJ
    Clin Exp Immunol; 2004 May; 136(2):341-8. PubMed ID: 15086400
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Macrophage Polarization in the Skin Lesion Caused by Neotropical Species of
    Sandoval Pacheco CM; Araujo Flores GV; Gonzalez K; de Castro Gomes CM; Passero LFD; Tomokane TY; Sosa-Ochoa W; Zúniga C; Calzada J; Saldaña A; Corbett CEP; Silveira FT; Laurenti MD
    J Immunol Res; 2021; 2021():5596876. PubMed ID: 33937417
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines.
    Banerjee A; Bhattacharya P; Joshi AB; Ismail N; Dey R; Nakhasi HL
    Cell Immunol; 2016 Nov; 309():37-41. PubMed ID: 27444130
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Can type-1 responses against intracellular pathogens be T helper 2 cytokine dependent?
    Alexander J; McFarlane E
    Microbes Infect; 2008 Jul; 10(9):953-9. PubMed ID: 18762265
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differential effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production.
    Leopoldo PT; Machado PR; Almeida RP; Schriefer A; Giudice A; de Jesus AR; Ho JL; Guimarães LH; Bacellar O; Carvalho EM
    BMC Infect Dis; 2006 Apr; 6():75. PubMed ID: 16638143
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major.
    Louzir H; Melby PC; Ben Salah A; Marrakchi H; Aoun K; Ben Ismail R; Dellagi K
    J Infect Dis; 1998 Jun; 177(6):1687-95. PubMed ID: 9607850
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Host-Directed Therapies for Cutaneous Leishmaniasis.
    Novais FO; Amorim CF; Scott P
    Front Immunol; 2021; 12():660183. PubMed ID: 33841444
    [TBL] [Abstract][Full Text] [Related]  

  • 74. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm.
    Alexander J; Bryson K
    Immunol Lett; 2005 Jun; 99(1):17-23. PubMed ID: 15894106
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Short-term protection conferred by Leishvacin® against experimental Leishmania amazonensis infection in C57BL/6 mice.
    Carneiro MB; de Andrade e Sousa LM; Vaz LG; Dos Santos LM; Vilela L; de Souza CC; Gonçalves R; Tafuri WL; Afonso LC; Côrtes DF; Vieira LQ
    Parasitol Int; 2014 Dec; 63(6):826-34. PubMed ID: 25102355
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CD8+ T cells are not required for vaccine-induced immunity against Leishmania amazonensis in IL-12/23P40(-/-) C57BL/6 mice.
    Hernández Sanabria MX; Afonso LC; Golgher D; Tafuri WL; Vieira LQ
    Microbes Infect; 2007 Jul; 9(9):1124-34. PubMed ID: 17662634
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Eosinophils and mast cells in leishmaniasis.
    Rodríguez NE; Wilson ME
    Immunol Res; 2014 Aug; 59(1-3):129-41. PubMed ID: 24838146
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the ugly.
    Novais FO; Scott P
    Semin Immunopathol; 2015 May; 37(3):251-9. PubMed ID: 25800274
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chemokines in Leishmaniasis: Map of cell movements highlights the landscape of infection and pathogenesis.
    de Araújo FF; Costa-Silva MF; Pereira AAS; Rêgo FD; Pereira VHS; de Souza JP; Fernandes LOB; Martins-Filho OA; Gontijo CMF; Peruhype-Magalhães V; Teixeira-Carvalho A
    Cytokine; 2021 Nov; 147():155339. PubMed ID: 33303311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.